TSXV · COV.V
Covalon Technologies Ltd.
CA$4.46-CA$0.04 (-0.89%)
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
Loading market information…
TSX · SVA.TO · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 07:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Sernova Corp.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sernova Corp.’s next earnings report is currently expected on Dec 18, 2026, with estimated earnings per share of -CA$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sernova Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -CA$0.02+36.88% vs estimate |
| CA$0.00 |
| Q4 2024 | Dec 23, 2024 | -CA$0.01+66.67% vs estimate | CA$0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$4.46-CA$0.04 (-0.89%)
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
CA$0.20CA$0.00 (0.0%)
Theralase Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.22% below the high.
CA$0.20CA$0.00 (0.0%)
Leef Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
CA$0.29CA$0.00 (0.0%)
Microbix Biosystems Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.12% below the high.
CA$0.05CA$0.00 (0.0%)
MedMira Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
CA$0.08+CA$0.01 (+6.67%)
Resverlogix Corp.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
CA$0.35CA$0.00 (0.0%)
Defence Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
